Mapping and Making Sense of Noncoding Mutations in the Genome Jiekun Yang and Mazhar Adli

Total Page:16

File Type:pdf, Size:1020Kb

Mapping and Making Sense of Noncoding Mutations in the Genome Jiekun Yang and Mazhar Adli Published OnlineFirst August 6, 2019; DOI: 10.1158/0008-5472.CAN-19-0905 Cancer Review Research Mapping and Making Sense of Noncoding Mutations in the Genome Jiekun Yang and Mazhar Adli Abstract Whole-genome sequencing efforts of tumors and normal introduction to the world of noncoding mutations. tissues have identified numerous genetic mutations, both We discuss recent progress in identifying noncoding muta- somatic and germline, that do not overlap with coding tions and the analytic and experimental approaches uti- genomic sequences. Attributing a functional role to these lized to interpret their functional roles. We also highlight noncoding mutations and characterizing them using exper- the potential mechanisms by which a noncoding mutation imental methods has been more challenging compared may exert its effect and discuss future challenges and with coding mutations. In this review, we provide a brief opportunities. Introduction to Germline and Somatic and cancer evolution is appreciated more and being intensely Variants studied. By whole-genome sequencing (WGS) of tens of thousands of No two humans are genetically identical. The genomes of two human tumors and matched controls (7–9), it becomes clear that unrelated individuals can be as much as 20 million base pairs both germline and somatic variants are not evenly distributed different from each other (or 0.6% of the total 3.2 billion base along the genome and they show similar patterns across critical pairs; ref. 1). We inherit these sequence variants from our parents. genomic elements at large scale. The genomic elements of concern They are present in all the cells of our body and are called germline usually include three types of open chromatin regions: RNA or variants. Certain germline variants have been linked to complex protein-coding gene body regions, promoters, and enhancers. The traits and disorders, including cancer (2). In addition to these latter two are major types of noncoding regulatory regions that inherited mutations, our cells also acquire novel mutations every control and fine tune the expression of genes. A promoter, located time they divide starting from a fertilized egg. Approximately near the transcription start sites (TSS) of a gene, is a region of DNA three mutations are estimated to occur when a normal human that initiates gene transcription, while an enhancer is a distal stem cell divides (3). These variants that are not inherited from a DNA-regulatory element that may be located as far as 1 Mb away parent and are usually not transmitted to offspring are called from the gene TSS. The enhancer elements regulate gene expres- somatic variants. These minor variations in the genomic sequence sion temporally and spatially, thus allowing cell type and tissue- may arise due to endogenous factors such as replication errors, specific gene expression. For germline variants, the protein-coding reactive oxygen species (ROS), aldehydes, mitotic errors, DNA genomic regions tend to accumulate far fewer variants than repair machinery deficiency, retrotransposons, or genome- intergenic regions, indicating stronger evolutionary conservation. modifying enzymes (4). In addition, environmental factors Interestingly, with the same standard applied, enhancer elements including chemicals, UV light, ionizing radiation, and viruses are more conserved than promoter elements (9). The spatial can also lead to genetic alterations in the somatic cells (4). As we distribution of somatic mutations in the cancer genome has age, somatic mutations accumulate in all our cells. A fraction of similar patterns. In human cancer cells, regions of open chromatin these mutations may positively contribute to cellular survival and exhibit decreased somatic mutation density compared with gene- proliferation. Thus, the cells harboring these mutations will be poor and heterochromatic genomic regions (10, 11). This selected within a tissue, which may end up acquiring the hall- decrease is likely due to the increased accessibility of these active marks of cancer (5). Because the somatic variation pool is large, no regions to the DNA repair machinery (12). It is notable that within two individuals' cancers are identical (6). As the understanding of the open chromatin regions, mutations tend to accumulate near how normal cells transform into cancer cells improves, the the transcription factor (TF)-binding sites such as at the promo- significance of germline and somatic variants in tumorigenesis ters (13). This may be caused by impaired DNA repair activity due to the physical presence of a TF (14). Alternatively, the TF-binding activity may directly create a local physical constraint on DNA, which may result in DNA strand breaks or exposure of ssDNA to Department of Biochemistry and Molecular Genetics, University of Virginia School of Medicine, Charlottesville, Virginia. APOBEC-like DNA-modifying enzymes (15). Various endoge- nous and exogenous factors such as replication errors, ROS, UV Corresponding Author: Mazhar Adli, University of Virginia, 1340 Jefferson Park light, and viruses contribute to the uneven variant Ave, Pinn Hall, Room: 6233, Charlottesville, VA 22902. Phone: 434-243-8567; – Fax: 434-924-5069; E-mail: [email protected] distribution (16 18), but not all the variants present are func- tional. From the millions of germline and somatic variants in the Cancer Res 2019;XX:XX–XX noncoding genomic region, the task of pinpointing a functional doi: 10.1158/0008-5472.CAN-19-0905 role for a specific noncoding variant and linking it to a biological Ó2019 American Association for Cancer Research. phenotype is not a trivial effort. Below, we will discuss some of the www.aacrjournals.org OF1 Downloaded from cancerres.aacrjournals.org on September 30, 2021. © 2019 American Association for Cancer Research. Published OnlineFirst August 6, 2019; DOI: 10.1158/0008-5472.CAN-19-0905 Yang and Adli efforts to identify such variants and potential approaches that can moters of PLEKHS1 (6.5%), WDR74 (4.2%), SDHD (10.2%), be taken to study the impact of noncoding variants. KIAA0907 (10.2%), and YAE1D1 (9.3%), and at the 50 UTR of TBC1D12 (15.2%) in tumors of different tissue origins (26, 27). Identification of Noncoding Mutations in Recently, small genomic windows with higher mutation rates are observed in specific cancer types. For example, noncoding muta- the Genome tions near DHX34 are observed in 43% of diffuse large B-cell Although theoretically, sequence variants between any two lymphoma and 29% of lymphomas and 17% of liver cancers have cells from an individual could be determined without accurate noncoding mutations in the regulatory region of TUBBP5 (28). It single-cell sequencing technologies, at present, only clonally should be noted that because multiple enhancers can regulate a expanded somatic mutations, for example, in the cancer context, single gene, combining mutations within a set of regulatory are reliably detected (4). Among the detected variants, identifying regions would further increase detection power (12). For exam- functional ones is another level of challenge. To this end, genome- ple, noncoding somatic and germline variants in several regula- wide association study(GWAS) and cancer genomics studies tory elements show a combinatorial effect on ESR1 expression in þ started with the basic assumption that functional variants are ER breast cancer (29). disproportionately presented in individuals (germline variants) or cells (somatic variants) with the trait of interest compared with Understanding Functional Roles of their control counterparts. As of February 2019, the NHGRI-EBI Catalog of published GWAS (https://www.ebi.ac.uk/gwas/) con- Noncoding Mutations tains 3,764 publications and 107,785 unique germline SNP that In the context of tumor evolution, recurrence of a genetic are associated with various biological traits, among which 5,256 alteration indicates that the particular mutation selectively con- are for cancer (19). It is notable that the vast majority of these tributes to cellular survival and proliferation. The real challenge is SNPs (94%) are within the noncoding genomic regions. GWASs to separate positively selected causal or driver variants from have been facilitated by the development of relatively inexpen- neutral passenger ones and mildly deleterious ones, and identify sive SNP arrays, which could be easily imputed to a large fully a functional role and the mechanism of action of such recurrent sequenced reference panel exploiting linkage disequilibri- noncoding mutations. um (20). However, cancer genomes rely on the identification In this respect, one proven approach is to integrate noncoding of somatic mutations through DNA sequencing. Currently, mutational data with other genomic data. Genomic, transcrip- approximately 6 million coding mutations have been identified tomic and epigenomic assays boost our understanding of the for approximately 1.5% of the genome, compared with 20 noncoding genome and its regulation of the coding genomic million noncoding mutations for approximately 98.5% of the regions. Taking advantage of the high-throughput assays, large- genome based on the Catalogue Of Somatic Mutations In scale projects such as the Encyclopedia of DNA Elements Cancerv86(COSMIC,https://cancer.sanger.ac.uk;ref.21).This (ENCODE; ref. 30) and Roadmap Epigenomics (31), revealed is largely due to the fact that a large fraction of cancer genome that up to 80% of the noncoding genome has regulatory func- sequencing efforts focused on exomes rather than whole tions. Thus
Recommended publications
  • Small Cell Ovarian Carcinoma: Genomic Stability and Responsiveness to Therapeutics
    Gamwell et al. Orphanet Journal of Rare Diseases 2013, 8:33 http://www.ojrd.com/content/8/1/33 RESEARCH Open Access Small cell ovarian carcinoma: genomic stability and responsiveness to therapeutics Lisa F Gamwell1,2, Karen Gambaro3, Maria Merziotis2, Colleen Crane2, Suzanna L Arcand4, Valerie Bourada1,2, Christopher Davis2, Jeremy A Squire6, David G Huntsman7,8, Patricia N Tonin3,4,5 and Barbara C Vanderhyden1,2* Abstract Background: The biology of small cell ovarian carcinoma of the hypercalcemic type (SCCOHT), which is a rare and aggressive form of ovarian cancer, is poorly understood. Tumourigenicity, in vitro growth characteristics, genetic and genomic anomalies, and sensitivity to standard and novel chemotherapeutic treatments were investigated in the unique SCCOHT cell line, BIN-67, to provide further insight in the biology of this rare type of ovarian cancer. Method: The tumourigenic potential of BIN-67 cells was determined and the tumours formed in a xenograft model was compared to human SCCOHT. DNA sequencing, spectral karyotyping and high density SNP array analysis was performed. The sensitivity of the BIN-67 cells to standard chemotherapeutic agents and to vesicular stomatitis virus (VSV) and the JX-594 vaccinia virus was tested. Results: BIN-67 cells were capable of forming spheroids in hanging drop cultures. When xenografted into immunodeficient mice, BIN-67 cells developed into tumours that reflected the hypercalcemia and histology of human SCCOHT, notably intense expression of WT-1 and vimentin, and lack of expression of inhibin. Somatic mutations in TP53 and the most common activating mutations in KRAS and BRAF were not found in BIN-67 cells by DNA sequencing.
    [Show full text]
  • Characterization of a Pediatric T-Cell Acute Lymphoblastic Leukemia Patient with Simultaneous LYL1 and LMO2 Rearrangements
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Erasmus University Digital Repository Articles and Brief Reports Acute Lymphoblastic Leukemia Characterization of a pediatric T-cell acute lymphoblastic leukemia patient with simultaneous LYL1 and LMO2 rearrangements Irene Homminga, 1 Maartje J. Vuerhard, 1 Anton W. Langerak, 2 Jessica Buijs-Gladdines, 1 Rob Pieters, 1 and Jules P.P. Meijerink 1 1Department of Pediatric Oncology/Hematology, Erasmus MC/Sophia Children’s Hospital, Rotterdam; and 2Department of Immunology, Erasmus MC, Rotterdam, The Netherlands ABSTRACT Translocation of the LYL1 oncogene are rare in T-cell acute consistently clustered along with cases having TAL1 or lymphoblastic leukemia, whereas the homologous TAL1 LMO2 rearrangements. Therefore, LYL1 -rearranged cases are gene is rearranged in approximately 20% of patients. not necessarily associated with immature T-cell develop - Previous gene-expression studies have identified an imma - ment, despite high LYL1 levels, but elicit a TALLMO expres - ture T-cell acute lymphoblastic leukemia subgroup with high sion signature. LYL1 expression in the absence of chromosomal aberrations. Molecular characterization of a t(7;19)(q34;p13) in a pediatric Key words: T-ALL, pediatric, LYL1, LMO2, rearrangements. T-cell acute lymphoblastic leukemia patient led to the identi - fication of a translocation between the TRB@ and LYL1 loci. Citation: Homminga I, Vuerhard MJ, Langerak AW, Buijs- Similar to incidental T-cell acute lymphoblastic leukemia Gladdines J, Pieters R, and Meijerink JPP. Characterization of a cases with synergistic, double translocations affecting pediatric T-cell acute lymphoblastic leukemia patient with simul - TAL1/2 and LMO1/2 oncogenes, this LYL1 -translocated taneous LYL1 and LMO2 rearrangements.
    [Show full text]
  • Regulation of Cdc42 and Its Effectors in Epithelial Morphogenesis Franck Pichaud1,2,*, Rhian F
    © 2019. Published by The Company of Biologists Ltd | Journal of Cell Science (2019) 132, jcs217869. doi:10.1242/jcs.217869 REVIEW SUBJECT COLLECTION: ADHESION Regulation of Cdc42 and its effectors in epithelial morphogenesis Franck Pichaud1,2,*, Rhian F. Walther1 and Francisca Nunes de Almeida1 ABSTRACT An overview of Cdc42 Cdc42 – a member of the small Rho GTPase family – regulates cell Cdc42 was discovered in yeast and belongs to a large family of small – polarity across organisms from yeast to humans. It is an essential (20 30 kDa) GTP-binding proteins (Adams et al., 1990; Johnson regulator of polarized morphogenesis in epithelial cells, through and Pringle, 1990). It is part of the Ras-homologous Rho subfamily coordination of apical membrane morphogenesis, lumen formation and of GTPases, of which there are 20 members in humans, including junction maturation. In parallel, work in yeast and Caenorhabditis elegans the RhoA and Rac GTPases, (Hall, 2012). Rho, Rac and Cdc42 has provided important clues as to how this molecular switch can homologues are found in all eukaryotes, except for plants, which do generate and regulate polarity through localized activation or inhibition, not have a clear homologue for Cdc42. Together, the function of and cytoskeleton regulation. Recent studies have revealed how Rho GTPases influences most, if not all, cellular processes. important and complex these regulations can be during epithelial In the early 1990s, seminal work from Alan Hall and his morphogenesis. This complexity is mirrored by the fact that Cdc42 can collaborators identified Rho, Rac and Cdc42 as main regulators of exert its function through many effector proteins.
    [Show full text]
  • Transcriptome Analyses of Rhesus Monkey Pre-Implantation Embryos Reveal A
    Downloaded from genome.cshlp.org on September 23, 2021 - Published by Cold Spring Harbor Laboratory Press Transcriptome analyses of rhesus monkey pre-implantation embryos reveal a reduced capacity for DNA double strand break (DSB) repair in primate oocytes and early embryos Xinyi Wang 1,3,4,5*, Denghui Liu 2,4*, Dajian He 1,3,4,5, Shengbao Suo 2,4, Xian Xia 2,4, Xiechao He1,3,6, Jing-Dong J. Han2#, Ping Zheng1,3,6# Running title: reduced DNA DSB repair in monkey early embryos Affiliations: 1 State Key Laboratory of Genetic Resources and Evolution, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, Yunnan 650223, China 2 Key Laboratory of Computational Biology, CAS Center for Excellence in Molecular Cell Science, Collaborative Innovation Center for Genetics and Developmental Biology, Chinese Academy of Sciences-Max Planck Partner Institute for Computational Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai 200031, China 3 Yunnan Key Laboratory of Animal Reproduction, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, Yunnan 650223, China 4 University of Chinese Academy of Sciences, Beijing, China 5 Kunming College of Life Science, University of Chinese Academy of Sciences, Kunming, Yunnan 650204, China 6 Primate Research Center, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, 650223, China * Xinyi Wang and Denghui Liu contributed equally to this work 1 Downloaded from genome.cshlp.org on September 23, 2021 - Published by Cold Spring Harbor Laboratory Press # Correspondence: Jing-Dong J. Han, Email: [email protected]; Ping Zheng, Email: [email protected] Key words: rhesus monkey, pre-implantation embryo, DNA damage 2 Downloaded from genome.cshlp.org on September 23, 2021 - Published by Cold Spring Harbor Laboratory Press ABSTRACT Pre-implantation embryogenesis encompasses several critical events including genome reprogramming, zygotic genome activation (ZGA) and cell fate commitment.
    [Show full text]
  • The Role of Noncoding Mutations in Blood Cancers Sunniyat Rahman and Marc R
    © 2019. Published by The Company of Biologists Ltd | Disease Models & Mechanisms (2019) 12, dmm041988. doi:10.1242/dmm.041988 REVIEW The role of noncoding mutations in blood cancers Sunniyat Rahman and Marc R. Mansour* ABSTRACT survival in adult acute myeloid leukaemia (AML) and ALL are The search for oncogenic mutations in haematological malignancies still less than 50%, with significant treatment challenges including has largely focused on coding sequence variants. These variants treatment-resistant disease, clonal heterogeneity of the underlying have been critical in understanding these complex cancers in greater disease, treatment-associated toxicities and poor tolerance for detail, ultimately leading to better disease monitoring, subtyping and intensive treatment regimens, particularly in older patients with prognostication. In contrast, the search for oncogenic variants in the comorbidities (Kansagra et al., 2018). Because of this, there is a noncoding genome has proven to be challenging given the vastness significant impetus to discover new genetic aberrations, including of the search space, the intrinsic difficulty in assessing the impact of driver mutations (see Box 1 for a glossary of terms), that may variants that do not code for functional proteins, and our still primitive provide insight into the mechanisms of malignant haematopoiesis, understanding of the function harboured by large parts of the as well as offering novel therapeutic opportunities. noncoding genome. Recent studies have broken ground on this Detailed genetic characterisation of haematological malignancies quest, identifying somatically acquired and recurrent mutations in the has already identified alterations that are now being used for better noncoding genome that activate the expression of proto-oncogenes. diagnosis, prognostication, subtype identification and to inform In this Review, we explore some of the best-characterised examples therapeutic decisions (Taylor et al., 2017).
    [Show full text]
  • The Polarity Protein Par6 Induces Cell Proliferation and Is Overexpressed in Breast Cancer
    Research Article The Polarity Protein Par6 Induces Cell Proliferation and Is Overexpressed in Breast Cancer Marissa E. Nolan,1,3 Victoria Aranda,3 Sangjun Lee,4 Balasubramanian Lakshmi,3 Srinjan Basu,2 D. Craig Allred,4 and Senthil K. Muthuswamy1,2,3 1Graduate Program in Genetics, Stony Brook University, Stony Brook, New York; 2Watson School ofBiological Sciences, 3Cold Spring Harbor Laboratory, Cold Spring Harbor, New York; and 4Department ofPathology and Immunology, Washington University School ofMedicine, St. Louis, Missouri Abstract proteins Cdc42/Rac (12–15). These interactions are required for The polarity protein complex Par6/atypical protein kinase Par6 regulation ofcell biological processes. For instance, Par6 (aPKC)/Cdc42 regulates polarization processes during regulates aPKC-induced phosphorylation ofLgl (16), Par1 (17), and epithelial morphogenesis, astrocyte migration, and axon Numb proteins (18) during establishment ofapical-basal polarity in epithelial cells. Likewise, Par6-associated aPKC regulates glycogen specification. We, as well as others, have shown that this h h complex is also required for disruption of apical-basal polarity synthase kinase 3 (GSK3 ) activity to induce polarized migration during the oncogene ErbB2-induced transformation and trans- ofastrocytes (19) and promote cell death during three-dimensional forming growth factor B–induced epithelial-mesenchymal epithelial morphogenesis (6). Thus, the Par6 complex can serve as a transition ofmammary epithelial cells. Here, we report that signaling node that regulates diverse biological processes by controlling activation ofdownstream pathways. expression ofPar6 by itselfin mammary epithelial cells induces epidermal growth factor–independent cell proliferation and In addition to its role during normal cell biology, Par6 also development ofhyperplastic three-dimensional acini without regulates initiation and progression ofcell transformation.For affecting apical-basal polarity.
    [Show full text]
  • LMO T-Cell Translocation Oncogenes Typify Genes Activated by Chromosomal Translocations That Alter Transcription and Developmental Processes
    Downloaded from genesdev.cshlp.org on September 25, 2021 - Published by Cold Spring Harbor Laboratory Press PERSPECTIVE LMO T-cell translocation oncogenes typify genes activated by chromosomal translocations that alter transcription and developmental processes Terence H. Rabbitts1 Medical Research Council (MRC) Laboratory of Molecular Biology, Division of Protein and Nucleic Acid Chemistry, Cambridge CB2 2QH, UK The cytogenetic analysis of tumors, particularly those of ment (immunoglobulin or T-cell receptor) occurs and oc- hematopoietic origin, has revealed that reciprocal chro- casionally mediates chromosomal translocation. This mosomal translocations are recurring features of these type of translocation causes oncogene activation result- tumors. Further from the initial recognition of the trans- ing from the new chromosomal environment of the re- location t(9;22) (Nowell and Hungerford 1960; Rowley arranged gene. In general, this means inappropriate gene 1973), it has become clear that particular chromosomal expression. The second, and probably the most common translocations are found consistently in specific tumor outcome of chromosomal translocations, is gene fusion subtypes. A principle example of this is the translocation in which exons from a gene on each of the involved chro- t(8;14)(q24;q32.1) invariably found in the human B cell mosomes are linked after the chromosomal transloca- tumor Burkitt’s lymphoma (Manolov and Manolov 1972; tion, resulting in a fusion mRNA and protein. This type Zech et al. 1976). The link with the immunoglobulin of event is found in many cases of hematopoietic tumors H-chain locus on chromosome 14, band q32.1 (Croce et and in the sarcomas. al. 1979; Hobart et al.
    [Show full text]
  • Analysis of the Indacaterol-Regulated Transcriptome in Human Airway
    Supplemental material to this article can be found at: http://jpet.aspetjournals.org/content/suppl/2018/04/13/jpet.118.249292.DC1 1521-0103/366/1/220–236$35.00 https://doi.org/10.1124/jpet.118.249292 THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS J Pharmacol Exp Ther 366:220–236, July 2018 Copyright ª 2018 by The American Society for Pharmacology and Experimental Therapeutics Analysis of the Indacaterol-Regulated Transcriptome in Human Airway Epithelial Cells Implicates Gene Expression Changes in the s Adverse and Therapeutic Effects of b2-Adrenoceptor Agonists Dong Yan, Omar Hamed, Taruna Joshi,1 Mahmoud M. Mostafa, Kyla C. Jamieson, Radhika Joshi, Robert Newton, and Mark A. Giembycz Departments of Physiology and Pharmacology (D.Y., O.H., T.J., K.C.J., R.J., M.A.G.) and Cell Biology and Anatomy (M.M.M., R.N.), Snyder Institute for Chronic Diseases, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada Received March 22, 2018; accepted April 11, 2018 Downloaded from ABSTRACT The contribution of gene expression changes to the adverse and activity, and positive regulation of neutrophil chemotaxis. The therapeutic effects of b2-adrenoceptor agonists in asthma was general enriched GO term extracellular space was also associ- investigated using human airway epithelial cells as a therapeu- ated with indacaterol-induced genes, and many of those, in- tically relevant target. Operational model-fitting established that cluding CRISPLD2, DMBT1, GAS1, and SOCS3, have putative jpet.aspetjournals.org the long-acting b2-adrenoceptor agonists (LABA) indacaterol, anti-inflammatory, antibacterial, and/or antiviral activity. Numer- salmeterol, formoterol, and picumeterol were full agonists on ous indacaterol-regulated genes were also induced or repressed BEAS-2B cells transfected with a cAMP-response element in BEAS-2B cells and human primary bronchial epithelial cells by reporter but differed in efficacy (indacaterol $ formoterol .
    [Show full text]
  • A Previously Unrecognized Promoter of LMO2 Forms Part of A
    Oncogene (2010) 29, 5796–5808 & 2010 Macmillan Publishers Limited All rights reserved 0950-9232/10 www.nature.com/onc ORIGINAL ARTICLE A previously unrecognized promoter of LMO2 forms part of a transcriptional regulatory circuit mediating LMO2 expression in a subset of T-acute lymphoblastic leukaemia patients SH Oram1, JAI Thoms2, C Pridans1, ME Janes2, SJ Kinston1, S Anand1, J-R Landry3, RB Lock4, P-S Jayaraman5, BJ Huntly1, JE Pimanda2 and B Go¨ttgens1 1Department of Haematology, Cambridge Institute for Medical Research, University of Cambridge, Cambridge, UK; 2Lowy Cancer Research Centre and The Prince of Wales Clinical School, University of New South Wales, Sydney, New South Wales, Australia; 3Institute for Research in Immunology and Cancer, Universite´ de Montre´al, Montre´al, Quebec, Canada; 4Children’s Cancer Institute Australia, University of New South Wales, Sydney, New South Wales, Australia and 5Birmingham University Stem Cell Centre, University of Birmingham, Edgbaston, Birmingham, UK The T-cell oncogene Lim-only 2 (LMO2) critically Introduction influences both normal and malignant haematopoiesis. LMO2 is not normally expressed in T cells, yet ectopic Lim-only 2 (LMO2), also known as TTG2 or RBTN2, expression is seen in the majority of T-acute lympho- was originally reported as a T-cell oncogene where it blastic leukaemia (T-ALL) patients with specific translo- was recurrently rearranged by chromosomal transloca- cations involving LMO2 in only a subset of these patients. tion in T-cell malignancies (Boehm et al., 1991; Royer- Ectopic lmo2 expression in thymocytes of transgenic mice Pokora et al., 1991). LMO2 encodes a 156 amino-acid causes T-ALL, and retroviral vector integration into the transcriptional co-factor containing two LIM domain LMO2 locus was implicated in the development of clonal zinc-fingers (Kadrmas and Beckerle, 2004) that do not T-cell disease in patients undergoing gene therapy.
    [Show full text]
  • Letters to the Editor
    LETTERS TO THE EDITOR The significant upregulation of Gata1 and EpoR mRNA Mice over-expressing human erythropoietin expression in hEPO over-expressing tg6 mice was con - indicate that erythropoietin enhances expression firmed by analyzing the spleen as a major source of of its receptor via up-regulated Gata1 and Tal1 hematopoiesis (Figure 2A and B). To further dissect the complexity of changes in the transcriptional network, the analysis of Myb mRNA expression served as marker for The development of medullary hematopoiesis is char - adult definitive erythroblasts, 10 showing significantly acterized by a specific expression profile of hematopoiet - ic transcription factors, including GATA transcription fac - tors. At mid-gestation, when hematopoiesis is newly A GATA 1 2 established in the bone marrow of human fetuses, initial - wt ly high GATA2 expression becomes subsequently down- regulated, while GATA1 expression increases in parallel. 1 1.5 Both transcription factors bind to overlapping sets of tg6 hematopoietic downstream target genes, often at distinct 1 sites, to regulate the balance between proliferation and differentiation. Chromatin occupancy by GATA1 and 0.5 GATA2 can change in the course of hematopoietic differ - entiation, leading to the so-called GATA switch. 2 Thus, a 0 n d7 d21 d49 i spatio-temporal regulation of GATA1 or GATA2 activities t c is required within lineage-specific differentiation. During a - erythroid differentiation GATA1 expression peaks at the b B GATA 2 3 o level of colony-forming units (CFU-E), where erythro - t 2 e poietin (Epo) exerts most specifically its effects, but v i t blocks terminal maturation if constitutively over- a 1.5 l 4 e expressed.
    [Show full text]
  • Rahman Et Al 2017 Somatically Acquired Activation of LMO2 in T-ALL
    Activation of the LMO2 oncogene through a somatically acquired neomorphic promoter in T-cell acute lymphoblastic leukemia The MIT Faculty has made this article openly available. Please share how this access benefits you. Your story matters. Citation Rahman, Sunniyat, Michael Magnussen, Theresa E. León, Nadine Farah, Zhaodong Li, Brian J. Abraham, Krisztina Z. Alapi, et al. “Activation of the LMO2 Oncogene through a Somatically Acquired Neomorphic Promoter in T-Cell Acute Lymphoblastic Leukemia.” Blood 129, no. 24 (March 7, 2017): 3221–3226. As Published https://doi.org/10.1182/blood-2016-09-742148 Publisher American Society of Hematology Version Author's final manuscript Citable link http://hdl.handle.net/1721.1/117283 Terms of Use Creative Commons Attribution-Noncommercial-Share Alike Detailed Terms http://creativecommons.org/licenses/by-nc-sa/4.0/ 1 Activation of the LMO2 oncogene through a somatically acquired 2 neomorphic promoter in T-Cell Acute Lymphoblastic Leukemia 3 4 Sunniyat Rahman1, Michael Magnussen1, Theresa E. León1, Nadine Farah1, Zhaodong Li2, 5 Brian J Abraham3, Krisztina Z. Alapi1, Rachel J. Mitchell1, Tom Naughton1, Adele K. 6 Fielding1, Arnold Pizzey1, Sophia Bustraan1, Christopher Allen1, Teodora Popa , Karin Pike- 7 Overzet5, Laura Garcia-Perez5, Rosemary E. Gale1, David C. Linch1, Frank J.T. Staal5, 8 Richard A. Young3,4, A. Thomas Look2,6, Marc R. Mansour1 9 10 1. University College London Cancer Institute, Department of Haematology, 72 Huntley 11 Street, London. WC1E 6DD. United Kingdom. 12 2. Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical 13 School, Boston, MA 02215 14 3. Whitehead Institute for Biomedical Research, 9 Cambridge Center, Cambridge, MA 15 02142 16 4.
    [Show full text]
  • Kobe University Repository : Thesis
    Kobe University Repository : Thesis Afadin Regulates Puncta Adherentia Junction Formation and 学位論文題目 Presynaptic Differentiation in Hippocampal Neurons(アファディンは海 Title 馬ニューロンにおいてアドへレンスジャンクションの形成と前シナプ スの分化を調節している) 氏名 Toyoshima, Daisaku Author 専攻分野 博士(医学) Degree 学位授与の日付 2014-03-25 Date of Degree 公開日 2015-03-01 Date of Publication 資源タイプ Thesis or Dissertation / 学位論文 Resource Type 報告番号 甲第6188号 Report Number 権利 Rights JaLCDOI URL http://www.lib.kobe-u.ac.jp/handle_kernel/D1006188 ※当コンテンツは神戸大学の学術成果です。無断複製・不正使用等を禁じます。著作権法で認められている範囲内で、適切にご利用ください。 PDF issue: 2021-09-26 Afadin Regulates Puncta Adherentia Junction Formation and Presynaptic Differentiation in Hippocampal Neurons アファディンは海馬ニューロンにおいてアドへレンスジャンクション の形成と前シナプスの分化を調節している 豊嶋大作, 萬代研二, 丸尾知彦、Irwan Supriyanto、 富樫英、井上貴仁、森正弘、高井義美 神戸大学大学院医学研究科医科学専攻 小児科学 (指導教員:飯島一誠 教授) 豊嶋大作 Key words: Afadin, puncta adherentia junction, presynapse, hippocampal neuron Manuscript Click here to download Manuscript: Toyoshima_text_revised_2nd_final.pdf 1 Afadin Regulates Puncta Adherentia Junction Formation and 2 Presynaptic Differentiation in Hippocampal Neurons 3 4 Daisaku Toyoshima1,3,4, Kenji Mandai1,3, Tomohiko Maruo1,3, Irwan Supriyanto2,3, 5 Hideru Togashi1,3, Takahito Inoue1,3, Masahiro Mori2,3 & Yoshimi Takai1,3 6 7 1. Department of Biochemistry and Molecular Biology, Kobe University Graduate 8 School of Medicine, Kobe, Hyogo 650-0047, Japan. 9 2. Faculty of Health Sciences, Kobe University Graduate School of Health Sciences, 10 Kobe, Hyogo 654-0142, Japan. 11 3. CREST, Japan Science and Technology Agency, Kobe, Hyogo 650-0047, Japan. 12 4. Present address: Department of Pediatrics, Kobe University Graduate School of 13 Medicine, Kobe, Hyogo 650-0017, Japan. 14 15 Correspondence should be addressed to Y.T. ([email protected]), K.M. 16 ([email protected]).
    [Show full text]